### 1 Systematic Review

# 2 Review and methodological analysis of trials currently testing treatment and 3 prevention options for COVID-19 globally.

4	Paraskevi C. Fragkou <sup>1,2,§,*</sup> , Drifa Belhadi <sup>3,4,§</sup> , Nathan Peiffer-Smadja <sup>3,5,¥</sup> , Charalampos
5	D. Moschopoulos <sup>1,¥</sup> , François-Xavier Lescure <sup>3,5</sup> , Hannah Janocha <sup>6</sup> , Emmanouil
6	Karofylakis <sup>1</sup> , Yazdan Yazdanpanah <sup>3,5</sup> , France Mentré <sup>3,4</sup> , Chrysanthi Skevaki <sup>2,6</sup> ,
7	Cédric Laouénan <sup>3,4,#</sup> , Sotirios Tsiodras <sup>1,2,#</sup> on behalf of the ESCMID Study Group for
8	Respiratory Viruses.
9	<sup>1</sup> 4 <sup>th</sup> Department of Internal Medicine, Medical School, National and Kapodistrian
10	University of Athens, Attikon University Hospital, Athens, Greece
11	<sup>2</sup> European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
12	Study Group for Respiratory Viruses (ESGREV)
13	<sup>3</sup> Université de Paris, IAME, INSERM, F-75018 Paris, France
14	<sup>4</sup> Département d'Epidémiologie Biostatistiques et Recherche Clinique, Hôpital Bichat
15	- Claude-Bernard, AP-HP, 75018 Paris, France
16	<sup>5</sup> Infectious Diseases Department, Bichat-Claude Bernard Hospital, Assistance-
17	Publique Hôpitaux de Paris, Paris, France
18	<sup>6</sup> Institute of Laboratory Medicine, Universities of Giessen and Marburg Lung Centre
19	(UGMLC), Philipps University Marburg, German Centre for Lung Research (DZL)
20	Marburg, Germany
21	*Corresponding author: Paraskevi C. Fragkou, 4th Department of Internal Medicine,

22 Medical School, National and Kapodistrian University of Athens, Attikon University

- 23 Hospital, Chaidari, Athens, 12462, Greece. Tel: +306973388299, Fax: +30
- 24 2105326446, Email: evita.fragou@gmail.com.
- 25 <sup>§</sup> Equal contribution as first authors
- 26  ${}^{\text{¥}}$  Equal contribution as second authors
- 27 <sup>#</sup>Equal contribution as senior authors
- 28 Abstract word count: 294 words
- 29 Main manuscript word count: 3873 words
- 30

#### 31 ABSTRACT

Background: As COVID-19 cases continue to rise globally within an unprecedented
short period of time, solid evidence from large randomised controlled trials is still
lacking. Currently, numerous trials testing potential treatment and preventative
options are undertaken globally.

36 Objectives: We summarised all currently registered clinical trials examining
37 treatment and prevention options for COVID-19. Additionally, we evaluated the
38 quality of the retrieved interventional studies.

39 Data sources: Clinicaltrials.gov, the Chinese Clinical Trial Registry and the European
40 Union Clinical Trials Register were systematically searched.

41 Study eligibility criteria: Registered clinical trials examining treatment and/or 42 prevention options for COVID-19 were included. No language, country or study 43 design restrictions were applied. We excluded withdrawn or cancelled studies and 44 trials not reporting therapeutic or preventative strategies for COVID-19.

45 Participants and interventions: No restrictions in terms of participants' age and
46 medical background or type of intervention were enforced.

Methods: The registries were searched using the term "coronavirus" or "COVID-19"
from their inception until 26<sup>th</sup> March 2020. Additional manual search of the registries
was also performed. Eligible studies were summarised and tabulated. Interventional
trials were methodologically analysed, excluding expanded access studies and trials
testing Traditional Chinese Medicine.

**Results:** In total, 309 trials evaluating therapeutic management options, 23 studies
assessing preventive strategies and 3 studies examining both were retrieved.

Interventional treatment studies were mostly randomised (n=150, 76%) and openlabel (n=73, 37%) with a median number of planned inclusions of 90 (IQR 40-200).Major categories of interventions that are currently being investigated are discussed.

58 **Conclusion:** Numerous clinical trials have been registered since the onset of the 59 COVID-19 pandemic. Summarised data on these trials will assist physicians and 60 researchers to promote patient care and guide future research efforts for COVID-19 61 pandemic containment. However, up to the end of March, 2020, significant 62 information on reported trials was often lacking.

63

64 Keywords: SARS-CoV-2; COVID-19; novel coronavirus; pneumonia; treatment;
65 prevention; antivirals; immunomodulators; anti-inflammatory; clinical trials.

#### 67 INTRODUCTION

68 COVID-19 pandemic induced by the Severe Acute Respiratory Syndrome 69 coronavirus 2 (SARS-CoV-2) has already affected most countries globally [1]. As of 70 April 12, 2020, more than 1,690,000 COVID-19 cases have been officially reported 71 leading to more than 150,900 deaths worldwide, with numbers constantly rising on a 72 daily basis as the virus continues to spread exponentially [2,3].

73 The original source of SARS-CoV-2 is still debatable, though phylogenetic data analysis converge into the hypothesis that SARS-CoV-2 has possibly originated from 74 75 bat SARS-like coronaviruses (CoVs) [4-6]. Human CoVs are positive-sense single-76 stranded RNA (+ssRNA) viruses belonging to the Orthocoronavirinae subfamily [7]. 77 The analysis of viral genome as well as structural and non-structural proteins plays 78 central role in identifying candidate treatment targets [7]. Notably, the SARS-CoV-2 79 surface spike glycoprotein (S-protein) is a key structural component that controls the 80 viral interaction with hosts' angiotensin I converting enzyme 2 (ACE2) receptor in order to invade human epithelial cells [8]. Moreover, molecules directed against non-81 82 structural proteins such as the viral protease or pathways imperative for viral genome 83 replication, alone or along with boosters or regulators of the host's immune system, 84 constitute promising therapeutic strategies[8,9].

Given the steep upsurge of COVID-19 cases worldwide within an unprecedented short period of time, we are still waiting for solid evidence from large randomised controlled trials regarding targeted antiviral treatments. In this systematic review, we aim firstly to summarise the data on all currently tested treatment and prevention options for the COVID-19 disease, and secondly to methodologically analyse and evaluate the quality of the registered interventional studies. 91

#### 92 METHODS

Registered clinical trials were systematically searched at the ClinicalTrials.gov 93 database[10], the Chinese Clinical Trial Registry[11] and the European Union 94 Clinical Trials Register [12] from their inception up to 26<sup>th</sup> March 2020 using the 95 96 search terms "coronavirus" or "COVID-19". Additional manual search of the 97 registries was performed for possibly unidentified studies. No language, country or 98 study design restrictions were applied. Participants of any age and medical background with or at risk for COVID-19 were included, as were any currently tested 99 intervention related to the treatment or prevention of COVID-19. 100

We excluded withdrawn or cancelled studies and trials not reporting therapeutic or
preventative measures for COVID-19. Eligible studies were summarised and
tabulated.

Methodological analysis of the interventional studies was performed. Traditional 104 105 Chinese Medicine (TCM) and homeopathy were excluded from the in-depth qualitative assessment, as we have no expertise to analyse clinical trials testing these 106 107 agents that rely on controversial scientific rationale [13,14]. We evaluated the study design, number of planned inclusions and primary outcomes of interventional studies, 108 109 excluding retrospective and "expanded access" studies. Studies were also analysed 110 according to their primary endpoint, i.e. clinical, virological (viral excretion in clinical 111 samples), radiological (imaging results such as CT-scan or X-rays), or biological / immunological (complete blood count, CR, CD8+/CD4+ T cells count, etc.). This 112 review was conducted according to the PRISMA guidelines [15]. 113

#### 115 **RESULTS**

#### 116 1. General data retrieved

In total, 335 studies were retrieved, including 309 trials evaluating therapeutic
molecules, devices and other management options, 23 studies assessing medications,
vaccines under development and other preventive strategies, and 3 studies examining
both (Figure 1, Table S1, Table S2). An overview of currently tested therapeutic
interventions is presented in Figure 2 and Figure 3.

122

#### 123 2. Main treatment interventions

124

#### 125 **Protease Inhibitors**

Lopinavir is a protease inhibitor (PI) activeagainst human immunodeficiency virus 1
(HIV-1) infection. The main coronavirus proteinase (3C-like proteinase or 3CL<sup>pro</sup>)
plays a key role in processing viral polyproteins [16,17]. PIs effectively inhibit the
3CL<sup>pro</sup> enzyme, thus posing a possibly potent therapeutic agent against SARS-CoV-2
infection.

131 PIs have shown effectiveness against SARS-CoV, MERS-CoV and SARS-CoV-2 132 viruses in *in vitro* susceptibility models [18–21]. During SARS-CoV epidemic, 133 lopinavir boosted by ritonavir (a cytochrome P450-3A4 inhibitor) with or without 134 ribavirin, significantly reduced adverse outcomes including mortality[22]. The 135 MIRACLE trial that examines the efficacy of ritonavir boosted lopinavir combined 136 with recombinant interferon-beta 1b (IFN-β1b) in the treatment of MERS, is currently 137 undertaken in Saudi Arabia and results are pending [23]. For COVID-19, lopinavir/ritonavir combined with or without other agents has been reported to successfully reduce adverse outcomes in sporadic cases from China [24– 27]. These promising reports have set the ground for numerous trials addressing the safety and efficacy of PIs in SARS-CoV-2 infection (Table 1). Other PIs that are currently being assessed are ritonavir boosted ASC09 (a novel PI), cobicistat boosted darunavir as well as the NS3/4A protease inhibitor danoprevir combined with ritonavir (Table 1, Table S1).

145

#### 146 **RNA polymerase inhibitors**

SARS-CoV-2 and SARS-CoV RNA-dependent RNA polymerase (RdRp) share 96%
sequence identity; this has justified the assumption that inhibitors effective against
SARS-CoV could have similar inhibitory effects against SARS-CoV-2[28].
Nucleoside analogues compete with natural nucleosides for the RdRp active site, thus
inhibiting the viral genome replication [29].Current research efforts focus on
repurposing older moleculesinCOVID-19 treatment, as their safety profile has already
been documented [30].

Remdesivir (GS-5734<sup>TM</sup>) is an adenosine analogue with broad-spectrum antiviral properties [31]. Preclinical data demonstrated the efficacy of remdesivir against SARS-CoV and MERS-CoV, as it has the potential to outcompete the proofreading ability of coronavirus exonuclease, and carries a high genetic resistance barrier [21,28,30,32]. Wang et al. confirmed its *in vitro* efficacy against SARS-CoV-2 [33].Currently, it is investigated in 7 randomised, controlled trials (Table 1, Table S1).

160 Favipiravir is a nucleoside analogue inhibiting the RNA polymerase, initially161 approved for the treatment of novel influenza viruses [34]. It is also effective against a

broad range of viruses, including positive-sense single-stranded RNA viruses [34].
Since there have been some promising *in vitro* results for its efficacy against SARSCoV-2, favipiravir is now being investigated in 8 clinical trials.

165 Ribavirin is a guanosine analogue that inhibits inosine monophosphate dehydrogenase 166 required for the synthesis of guanosine triphosphate, leading to lethal mutagenesis of 167 RNA genome [35]. Ribavirin was used in SARS epidemic in combination with either 168 lopinavir/ritonavir or interferon alpha (IFN- $\alpha$ ), and these combinations are currently 169 recommended by the China National Practice Guidelines for the treatment of severe 170 COVID-19 [22,36].

171 Azvudine, an azidocytidine analogue that inhibits viral reverse transcriptase, has been 172 effective against HIV, hepatitis B and C viruses [37]. Its efficacy against SARS-CoV-2 is being tested in 3 ongoing clinical trials (Table 1, Table S1). Another nucleoside 173 174 analogue undergoing investigation for COVID-19 pneumonia is emtricitabine/tenofovir alafenamide. 175

176

#### 177 Anti-malaria drugs

178 Chloroquine and hydroxychloroquine are currently licensed for the treatment of malaria and autoimmune diseases [38]. However, they have also been studied against 179 several viruses with promising in vitro results, never confirmed in humans [39-41]. 180 181 As weak bases, they are concentrated in acidic intra-cellular organelles, leading to alkalization and distraction of the low pH-dependent steps of viral replication, 182 including viral-cell fusion and uncoating [38,40]. Moreover, they impair the terminal 183 184 glycosylation of ACE2 receptor in Golgi apparatus, thus inhibiting the viral penetration into the host cells [42]. 185

As they are accumulated in lymphocytes and macrophages, these drugs reduce 186 187 secretion of proinflammatory cytokines, and particularly of tumour necrosis factor 188 alpha (TNF- $\alpha$ ) [41]. Experimental data demonstrated that chloroquine is highly 189 effective in vitro against SARS-CoV-2 in an estimated effective concentration that is 190 easily achievable with standard dosing regimens [33]. Preliminary results from small 191 studies suggested the effectiveness of chloroquine, alone or combined with 192 azithromycin, in viral clearance, inhibition of pneumonia exacerbation, improvement 193 of lung imaging and shortening of the disease course [43,44]. However, clinical trials 194 with a control group are needed to provide reliable answers for clinicians.

195

#### 196 Immunomodulators and anti-inflammatory drugs

197 Virus-induced exuberant immune response leading to cytokine storm syndrome (CSS) 198 and secondary haemophagocytic lymphohistiocytosis (HLH) is probably the 199 underlying pathogenetic mechanism that leads to critical and often fatal COVID-19 200 infection [45,46]. Hyperinflammation is associated with acute respiratory distress 201 syndrome (ARDS) and fulminant multi-organ failure thatarefatal if left untreated. In 202 this context, immunosuppressors (along with antivirals) may play a key role in 203 counteracting severe SARS-CoV-2 infection [45].

Preliminary data from COVID-19 patients in China reported significantly higher interleukin (IL)-6 levels in patients with critical COVID-19 disease than those with severe or mild disease [47]. Tocilizumab and sarilumab, both humanised monoclonal antibodies (mAbs) against the IL-6 receptor, are currently evaluated in 14 clinical trials (Table 1, Table S1); tocilizumab, in particular, improved symptoms and laboratory parameters in a small retrospective study in China [48]. Various other 210 molecules oriented against different cytokines, as well as intra- and extra-cellular inflammatory pathways, are currently being tested in COVID-19 including: 211 212 adalimumab, anti-programmed cell death protein 1 mAbs, bevacizumab, ixekizumab, eculizumab, human recombinant IL-2, inhibitors of NLRP3 inflammasome activation 213 214 (tranilast), Janus Kinase inhibitors, fingolimod and a recombinant fusion protein 215 targeting an immune pathway checkpoint (CD24Fc).Clinical trials on other 216 immunotherapies (i.e.gimsilumab, siltuximab, lenzilumab and leronlimab) have been 217 proposed, but havenot been registered yet.

Immunomodulators licensed for haematological and rheumatological conditions (such
as leflunomide and thalidomide), as well as colchicine that counteracts the assembly
of the NLRP3 inflammasome, are also being studied for their therapeutic use against
SARS-CoV-2 (Table 1,Table S1) [49].

The immunomodulatory effects of macrolide antibiotics, as well as their pharmacodynamic property to achieve at least 10-fold higher concentrations in epithelial lung fluid than in serum, have led researchers to repurpose them against SARS-CoV-2 (Table 1, Table S1) [50,51]. Preliminary results of a study have shownsignificant viral load reduction in patients treated withhydroxychloroquine plus azithromycin [43].

Corticosteroids are major anti-inflammatory drugs, with a conflicting safety profile in
severe viral infections [52]. However, their use currently recommended by the
European Society of Intensive Care Medicine in COVID-19 cases with shock and/or
evidence of CSS/HLH and/or mechanically ventilated patients with ARDS [53].
Corticosteroids are being tested in 11 clinical trials (Table 1, Table S1).

Finally, immunostimulatory molecules that enhance the hosts' immune response against the invading pathogen, like IFN-α, interferon beta (IFN-β), the recombinant protein produced by DNA-shuffling of IFN-α (novaferon), the inactivated *Mycobacterium* vaccine and thymosin a1, are evaluated as viable therapeutic options in various combinations against SARS-CoV-2 [54].

238

#### 239 Membrane fusion inhibitors and inhibitors of ACE2 receptor connection

SARS-CoV-2S-protein bindsACE2 receptor on the epithelial cells' membrane [55].
The host's type II transmembrane serine protease (TMPRSS2) facilitates membrane
fusion and augments viral internalization by cleaving and activating the S-protein
[56,57]. These proteins, being an integral part of the viral life cycle, can be used as
possible therapeutic targets.

245 ACE inhibitors (ACEi) selectively inhibit ACE1 but not ACE2, as they are 246 structurally different enzymes [58]. Experimental animal models show that 247 angiotensin II type 1 receptor blockers (ARBs) and ACEi may up-regulate ACE2 expression; although this raised concerns that ACEi and ARBs may be associated 248 with a more severe form of COVID-19, there is no evidence supporting that ACE2 249 250 up-regulation augments the virulence or the penetration of the virus into the hosts' 251 cells as of yet [58,59]. Contrarily, renin-angiotensin system (RAS) inhibition may 252 ameliorate the over-accumulation of angiotensin II induced by the down-regulation of 253 ACE2 noted in other CoVs infection, thus possibly protecting against the development of fulminant myocarditis and ARDS [58]. In spite of controversial data, 254 255 2 randomised controlled trialstesting losartan are currently undertaken in the USA.

Camostat mesilate is a potent serine protease inhibitor, inhibiting the TMPRSS2 and is approved for chronic pancreatitis [60]. *In vitro* experiments have shown that camostat is effective against SARS-CoV-2[61]. Nafamostat, another inhibitor of TMPRSS2 has been suggested in COVID-19 therapy, but no registered trials are available yet.

Umifenovir is a small indole derivative with a broad-spectrum antiviral activity 261 developed about 30 years ago [62,63]. Although it is currently used in Russia and 262 263 China to combat influenza, it has shown in vitro activity against numerous DNA and RNA viruses including SARS-CoV [62,64,65]. It primarily targets the interaction 264 265 between viral capsid and the membrane of the host cell by inhibiting the attachment, 266 the fusion and the internalization of the virus [62]. Moreover, umifenovir has direct 267 virucidal effects against enveloped viruses through interaction with the viral lipid 268 envelope or with key residues within structural proteins of virions [62,65,66]. Limited 269 data support that umifenovir may exhibit immunomodulatory effects by stimulating hosts' humoral immune response, interferon production, and phagocytes' activation 270 271 [67]. A small retrospective study in China demonstrated some promising results regarding its effectiveness against SARS-CoV-2 when used in combination with 272 273 lopinavir/ritonavir [68]. Currently 11 relevant clinical trials are in progress globally (Table 1, Table S1). 274

275

#### 276 Passive immunization

The use of convalescent plasma (CP) to passively immunise patients against viral pathogens has been previously reported, especially when no other treatment options wereavailable [69]. CP obtained from recovering patients was used during the SARS

epidemic; two retrospective studies demonstrated that CP administration in SARS
patients reduced duration of hospitalisation and mortality rates, when treatment with
ribavirin and corticosteroids failed [70–72].

A meta-analysis of patients with severe respiratory infection induced by various 283 viruses showed a statistically significant reduction of 75% in mortality odds in those 284 who received CP across all viral aetiologies, including the influenza A 2009 pandemic 285 strain (H1N1pdm09) and SARS-CoV[73]. Evidence of survival benefit was noted 286 287 after early administration, while no serious adverse effects were reported. Although results are pending from 10 relevant clinical trials, the potential short-lasting 288 289 immunity after CoV infection has raised uncertaintyregardingthe clinical efficacy of 290 CP antibodies in clinical practice[74,75].

291

#### 292 Cell therapies

Mesenchymal stromal cells (MSCs) exhibit immunomodulating qualities, may skew 293 294 immune cell differentiation and have shown promise in H5N1-associated acute lung injury in preclinical models[76]. A pilot study involving MSC transplantation in 7 295 patients with COVID-19 resulted in cure or significant improvement of pulmonary 296 297 function and symptoms without adverse effects [77]. MSCs may partially accumulate 298 in lungs and improve the pulmonary microenvironment. A significant induction of regulatory dendritic cells(DCs), along with a shift from Th1 towards Th2 immune 299 300 responses, was also observed [77]. Other clinical trials utilizing MSCs for curing COVID-19 are ongoing (Table 1, Table S1). 301

302 MSC-derived exosomes are extracellular bodies mediating intercellular
303 communication, containing mRNAs, miRNAs, lipids, growth factors and cytokines,

that possibly exert the paracrine immunoregulatory effects of MSC [78]. Furthermore,
MSC-exosomes' administration is associated with lower risks (e.g.tumour formation,
immunogenicity) compared to the intravenous injection of MSCs [79].

Natural killer cells have shown promising results as adoptive immunotherapy in
various cancers, and may also be potent effector cells in the SARS-CoV-2 infection.
A phase 1 clinical trial has been launched to determine their efficacy (Table S1).
Lastly, ozone therapy may inactivate viruses, among other pathogens, and activate the
immune system via up-regulation of Th1 cytokines including IFN and TNF; as such,3
trials have been launched to evaluate ozone autohaemotherapy efficacy in COVID-19
[80].

314

#### 315 **3.** Main preventative measures

The World Health Organization (WHO) and the European Centre for Disease Prevention and Control (ECDC) emphasise the role of screening, precaution measures, exposure prevention and environmental disinfection as the mainstay of COVID-19 prevention[81,82]. As no effective preventative options are available yet, several clinical trials are under way to explore the efficacy of various prevention strategies (Table 2, Table S2).

Many studies are currently evaluating the efficacy of TCM in COVID-19 prevention in China. Importantly, at least 4 vaccines are under development. Among them, an mRNA-based vaccine encoding the S-protein is being assessed for its safety, reactogenicity and efficacy against SARS-CoV-2 (Table 2, Table S2). Besides the registered trials, other large companies have also announced the initiation of vaccine development [83,84]. 328 Other preventative molecules include hydroxychloroquine and the recombinant 329 human interferon  $\alpha$ 1b spray. In the USA, exposed individuals are randomised to 330 hydroxychloroquine or placebo, evaluating the agent'spotential as post-exposure prophylaxis (NCT04308668, Table S2). Furthermore, another randomised clinical 331 332 trial evaluates the efficacy of a 3-month course of chloroquine in at-risk healthcare 333 personnel (NCT04303507, Table S2). Finally, the live attenuated strain of 334 Mycobacterium bovis is expected to be tested as a preventative strategy against 335 COVID-19 among healthcare professionals, in Australia and France.

336

#### 337 4. Methodological analysis of interventional studies

#### 338 Study Populations

339 In total, 198 interventional treatment and 16prevention trials were included in the 340 methodological analysis respectively (Table 3). Among the eligible treatment studies, children recruitment (i.e.< 14 years old) was reported in 7 clinical trials in total: 1 341 342 testing darunavir with cobicistat (NCT04252274); 2 on human stem cells transfusion (ChiCTR2000029606, ChiCTR2000030944); 1 testing 343 hydroxycholoroquine (EudraCT Number: 2020-000890-25); 1 using tocilizumab (NCT04317092); and 1 344 assessing nutritional supplements (NCT04323345) (Table S1).With respect to 345 346 prevention studies, children included in 2 vaccine relevant were trials(NCT04276896and NCT04299724) as shown in Table S2. 347

348

#### 349 Study designs

Phase IV and phase III treatment trials were the most commonly reported
interventional study types (n=40, 20% and n=35, 18% respectively) as demonstrated
in Table 3. Nonetheless, the majority of registered trials do not disclose the study
phase (n=83, 42%).

In terms of blinding, 73 open-label (37%), 31 double-blinded (16%), and 16 singleblinded (8%) studies were retrieved. Most trials were randomised (n=150, 76%) with a parallel assignment between arms. The median (IQR) number of planned inclusions

is 90 (40-200) with a range of 5 to 6000 participants.

Phase III and phase I prevention studies were the most commonly reported ones (n=6,
38% and n=3, 19% respectively, Table3). As with treatment trials, many prevention
trials do not report the study phase (n=4, 25%).

361 Regarding prevention studies' blinding, 6double-blinded (38%), 5open-label (31%),

and 2 single-blinded (13%) were found. Most studies were randomised (n=10, 63%)

363 with a parallel assignment design. The median (IQR) number of planned inclusions is

364 513 (177-2958) ranging from 45 to 7576 participants.

365

#### **366** Treatments and interventions

Various types of interventions are currently evaluated; however, their appraisal is limited by the lack of reported data concerning the treatment dose and duration. Figure 4 demonstrates the number of trials by the median of planned inclusions per trial for the ten most frequently encountered therapies. Although remdesivir is tested in only 7 trials, these studies have the highest median number of planned inclusions per trial (453, IQR 397-650). On the other hand, cell therapies are assessed by the highest number of trials (n=25), but with a disproportionately low median number of
planned inclusions (30, IQR 20-60). Figure 5 shows the total number of planned
inclusions and the number of clinical trials for the ten most frequently studied
treatments, with hydroxychloroquine being the treatment associated with the highest
total number (10,146 planned iclusions).

378

379 Primary endpoints and outcomes

380 A clinical primary outcome was defined in 128 therapeutic trials (65%; Table 3); most 381 of them focused on the symptoms' evolution such as time to clinical recovery, the 382 proportion of patients with clinical improvement or deterioration, length of 383 hospitalisation or mortality. A number of scores are utilized as primary outcomes such 384 as the ordinal 7-point scale adapted from the WHO master protocol, the lung injury score, the pneumonia severity index or the National Early Warning Score 2 score [85– 385 87]. Most prevention studies disclose a clinical primary outcome (13 studies, 81%), 386 387 while virological, radiological and biological/immunological primary endpoints were 388 reported in 39 (20%), 19 (10%), and 12 (6%) studies respectively (Table 3).

389

#### **390 DISCUSSION**

The SARS-CoV-2 is the third emerging coronavirus of the last 20 years, but the one that has led to an evolving pandemic, a fact that urgently requires the implementation of novel therapeutics. However, repurposing of existing drugs is a viable and less time-consuming alternative; licensed broad-spectrum antiviral agents with a welldocumented safety profile are currently tested against SARS-CoV-2. Alternatively, 396 screening of chemical compounds' libraries may be useful in the discovery of an 397 efficacious treatment against COVID-19 disease [8]. In this review, we have 398 summarised and methodologically appraised the ongoing therapeutic and preventive 399 trials for COVID-19.

Therapeutic strategies should follow the two-phased immune response to COVID-19. 400 401 Initially, treatment should aim at strengthening the host's immune response against the 402 virus, and inhibiting the viral replication [88]. Early initiation of antiviral therapy has 403 been proved beneficial for the prognosis of patients[89]. As advanced age correlates with higher viral loads, older patients could strongly benefit from the prompt 404 405 initiation of antivirals[90]. Moreover, high inflammatory cytokine levels have been 406 correlated with disease severity and the extent of lung damage[91]. Thus, in the later 407 phase of the infection, patients could be availed by anti-inflammatory therapeutic approaches such as the Janus kinase inhibitors, blood purification or tocilizumab 408 409 [92,93].

410 The Chinese National Health Commission recommends antiviral therapy with the 411 protease inhibitors lopinavir/ritonavir. Other recommended antiviral agents include 412 interferon alpha and chloroquine phosphate [93]. Advantages of chloroquine include 413 its long clinical history, known side effects and low cost, which render it a good 414 candidate for global use[33]. The broad-spectrum antiviral agent remdesivir has 415 successfully been used in individual COVID-19 cases by the Washington Department 416 of Health[94]. Effectiveness of both chloroquine and remdesivir against COVID-19 417 remains to be seen in ongoing trials.

Prevention is a key player in combating pandemics. The mRNA 1273 vaccine, iscurrently in phase I, but is not expected to be commercially available this year[95].

The prophylactic potential of hydroxychloroquine/chloroquine is also actively being examined among healthcare professionals[96]. Moreover, prompt testing and isolation are of utmost importance for disease prevention. At the moment, real-time quantitative polymerase chain reaction is the reference standard in diagnostics [97]. The FDA has recently announced the authorisation of rapid molecular tests that are capable of delivering results within minutes, thus facilitating early treatment initiation(when viral loads are highest) and timely isolation[90,98,99].

Based on the retrieved data, cell therapies and hydroxychloroquine were the most frequently evaluated candidate therapies (25 and 22 trials respectively), while remdesivir was associated with the highest median number of planned inclusions per trial (453, IQR 397-650).Although TCMs and homeopathy represent a large proportion of the identified interventional studies, we excluded them from our methodological analysis as we do not have the expertise to analyse clinical trials testing these agents.

This review shows the considerable amount of clinical trials that are currently registered. Although the number of identified trials was high, there were several methodological caveats. Firstly, study design data and details on the interventions being assessed were often lacking. This hampers the available information to researchers and relevant stakeholders, and potentially influences the discovery of successful treatments.

440 Secondly, most trials, and especially those registered at the beginning of the 441 pandemic, disclosed low participant numbers, which may impact the robustness of 442 their future results. However, these numbers should be cautiously interpreted, as they 443 represent the anticipated, and not the actual number of inclusions. Thirdly, reported

444 primary endpoints were highly heterogeneous among studies. In our opinion, the 445 application clinical primary endpoints should be encouraged in an infection where 446 the association between the clinical status and viral clearance, radiological or 447 immunological evolution is obscure.

The identification of the best therapeutic approach is challenging, especially in the 448 context of a pandemic with thousands of casualties. Our study underlines the need to 449 meticulously register as many study details as possible on international registries 450 451 during outbreaks, in order to guide the development and enhance the consistency of 452 future trials. The development of clinical trials during an outbreak is an adaptive 453 process and new evidence emerges at an impressive rate. A review of the early 454 registered clinical trials is an important asset for researchers and methodologists. 455 These results might encourage transparency when developing and registering future 456 clinical trials and help improve their methodology, hence the robustness of their 457 results.

In the absence of reliable vaccines and therapies, disease containment plays a pivotal role, as has been recently observed in China. Undertaking actions such as nationwide temperature measurements, health recommendations, detection and strict isolation proved to slow down the transmission rate [100]. The time thereby won is precious for the development of therapies and vaccines. This approach is especially useful for countries with weaker health systems that lack sufficient medical supplies and infrastructure, and often depend on the support of the international community.

465

#### 466 Transparency declaration

467 *Conflict of interest*: For YY: Chair of the Global Research Collaboration for
468 Infectious Disease Preparedness (GloPID-R) and the coordinator of REsearch and
469 ACTion targeting emerging infectious diseases (REACTing).

For CS: Consultancy and research funding, Hycor Biomedical and Thermo Fisher 470 Scientific; Consultancy, BencardAllergie; Research Funding, Mead Johnson Nutrition 471 472 (MJN). Supported by Universities Giessen and Marburg Lung Centre (UGMLC), the German Centre for Lung Research (DZL), University Hospital Giessen and Marburg 473 474 (UKGM) research funding according to article 2, section 3 cooperation agreement, and the Deutsche Forschungsgemeinschaft (DFG)-funded-SFB 1021 (C04), -KFO 475 476 309 (P10), and SK 317/1-1 (Project number 428518790). All grants are outside the 477 submitted work.

478 *Funding*: No external funding was received for this study.

*Author contributions*: Conception and design: PCF, ST, DB, NPS, FM, CL.
Acquisition of data: PCF, EK, CDM, HJ, CS, DB, NPS, YY. Interpretation of data: all
authors. Drafting the article: PCF, EK, CDM, HJ, CS, DB, NPS, FM, CL, YY.
Revising critically the manuscript for important intellectual content: PCF, CS, ST.
PCF and DB contributed equally as first authors, CDM and NPS contributed equally
as second authors, CL and ST contributed equally as senior authors. All authors
approved the final version of the manuscript submitted.

486

#### 487 **REFERENCES**

488 [1] Interim Guidance: Healthcare Professionals 2019-nCoV | CDC n.d.
489 https://www.cdc.gov/coronavirus/2019-nCoV/hcp/clinical-criteria.html

490 (accessed April 2, 2020).

- 491 [2] Situation reports n.d. https://www.who.int/emergencies/diseases/novel-
- 492 coronavirus-2019/situation-reports/ (accessed April 2, 2020).
- 493 [3] Coronavirus disease 2019 (COVID-19) pandemic: increased transmission in
  494 the EU/EEA and the UK seventh update. n.d.
- 495 [4] Paraskevis D, Kostaki EG, Magiorkinis G, Panayiotakopoulos G, Sourvinos G,
- 496 Tsiodras S. Full-genome evolutionary analysis of the novel corona virus (2019-
- 497 nCoV) rejects the hypothesis of emergence as a result of a recent

498 recombination event. Infect Genet Evol 2020;79:104212.

- 499 https://doi.org/10.1016/j.meegid.2020.104212.
- 500 [5] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
- 501 epidemiology of 2019 novel coronavirus: implications for virus origins and
- 502
   receptor binding. Lancet 2020;395:565–74. https://doi.org/10.1016/S0140 

   672 (620)20251 0
   672 (620)20251 0
- **503** 6736(20)30251-8.
- 504 [6] Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M.
- 505The 2019-new coronavirus epidemic: Evidence for virus evolution. J Med
- 506 Virol 2020;92:455–9. https://doi.org/10.1002/jmv.25688.
- 507 [7] Harrison C. Coronavirus puts drug repurposing on the fast track. Nat
  508 Biotechnol 2020. https://doi.org/10.1038/d41587-020-00003-1.
- 509 [8] Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV).
- 510 Biosci Trends 2020;14:69–71. https://doi.org/10.5582/bst.2020.01020.
- 511 [9] Zhang L, Liu Y. Potential interventions for novel coronavirus in China: A
  512 systematic review. J Med Virol 2020;92:479–90.
- 513 https://doi.org/10.1002/jmv.25707.
- 514 [10] Home ClinicalTrials.gov n.d. https://clinicaltrials.gov/ (accessed April 2, 2020).
- 516 [11] Chinese Clinical Trial Register (ChiCTR) The world health organization

517		international clinical trials registered organization registered platform n.d.
518		http://www.chictr.org.cn/searchprojen.aspx (accessed April 2, 2020).
519	[12]	EU Clinical Trials Register - Update n.d. https://www.clinicaltrialsregister.eu/
520		(accessed April 2, 2020).
521	[13]	Hard to swallow. Nature 2007;448:105-6. https://doi.org/10.1038/448106a.
522	[14]	Ernst E. Homeopathy, a "helpful placebo" or an unethical intervention? Trends
523		Pharmacol Sci 2010;31:1. https://doi.org/10.1016/j.tips.2009.10.005.
524	[15]	Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al.
525		Preferred reporting items for systematic reviews and meta-analyses: The
526		PRISMA statement. PLoS Med 2009;6.
527		https://doi.org/10.1371/journal.pmed.1000097.
528	[16]	Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. $\alpha$ -Ketoamides as
529		Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication:
530		Structure-Based Design, Synthesis, and Activity Assessment. J Med Chem
531		2020. https://doi.org/10.1021/acs.jmedchem.9b01828.
532	[17]	Fan K, Wei P, Feng Q, Chen S, Huang C, Ma L, et al. Biosynthesis,
533		purification, and substrate specificity of severe acute respiratory syndrome
534		coronavirus 3C-like proteinase. J Biol Chem 2004;279:1637–42.
535		https://doi.org/10.1074/jbc.M310875200.
536	[18]	Nukoolkarn V, Lee VS, Malaisree M, Aruksakulwong O, Hannongbua S.
537		Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-
538		CoV 3CL(pro) inhibitors. J Theor Biol 2008;254:861-7.
539		https://doi.org/10.1016/j.jtbi.2008.07.030.
540	[19]	Chen F, Chan KH, Jiang Y, Kao RYT, Lu HT, Fan KW, et al. In vitro
541		susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral

542 compounds. J Clin Virol 2004;31:69–75.

- 543 https://doi.org/10.1016/j.jcv.2004.03.003.
- 544 [20] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van
- 545 Nieuwkoop S, Bestebroer TM, et al. Screening of an FDA-approved compound
- 546 library identifies four small-molecule inhibitors of Middle East respiratory
- 547 syndrome coronavirus replication in cell culture. Antimicrob Agents
- 548 Chemother 2014;58:4875–84. https://doi.org/10.1128/AAC.03011-14.
- 549 [21] Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al.
- 550 Comparative therapeutic efficacy of remdesivir and combination lopinavir,
- ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020;11:222.
  https://doi.org/10.1038/s41467-019-13940-6.
- 553 [22] Chu CM, Cheng VCC, Hung IFN, Wong MML, Chan KH, Chan KS, et al.
- Role of lopinavir/ritonavir in the treatment of SARS: initial virological and
  clinical findings. Thorax 2004;59:252–6.
- 556 https://doi.org/10.1136/thorax.2003.012658.
- 557 [23] Arabi YM, Alothman A, Balkhy HH, Al-Dawood A, AlJohani S, Al Harbi S, et
- al. Treatment of Middle East Respiratory Syndrome with a combination of
- 559 lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a
- randomized controlled trial. Trials 2018;19:81. https://doi.org/10.1186/s13063017-2427-0.
- 562 [24] Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. [Management of corona virus
  563 disease-19 (COVID-19): the Zhejiang experience]. Zhejiang Da Xue Xue Bao
  564 Yi Xue Ban 2020;49:0.
- 565 [25] Han W, Quan B, Guo Y, Zhang J, Lu Y, Feng G, et al. The course of clinical
  566 diagnosis and treatment of a case infected with coronavirus disease 2019. J
  567 Med Virol 2020;92:461–3. https://doi.org/10.1002/jmv.25711.
- 568 [26] Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index

- 569 patient who caused tertiary transmission of coronavirus disease 2019 in Korea:
- 570 The application of lopinavir/ritonavir for the treatment of COVID-19
- 571 pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 2020;35.
- 572 https://doi.org/10.3346/jkms.2020.35.e79.
- 573 [27] Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and
- therapeutic procedure for four cases with 2019 novel coronavirus pneumonia
  receiving combined Chinese and Western medicine treatment. Biosci Trends
  2020;14:64–8. https://doi.org/10.5582/bst.2020.01030.
- 577 [28] Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent
- 578 Prevention and Treatment Options for Severe Acute Respiratory Infections
- 579 Caused by 2019-nCoV. Chembiochem 2020;21:730–8.
- 580 https://doi.org/10.1002/cbic.202000047.
- 581 [29] Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.

582 Life Sci 2020;248:117477. https://doi.org/10.1016/j.lfs.2020.117477.

- 583 [30] Martinez MA. Compounds with therapeutic potential against novel respiratory
- 584 2019 coronavirus. Antimicrob Agents Chemother 2020:1–18.
- 585 https://doi.org/10.1128/AAC.00399-20.
- 586 [31] Warren TK, Jordan R, Lo MK, Ray AS, Mackman RL, Soloveva V, et al.
- 587 Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in
- 588 rhesus monkeys. Nature 2016;531:381–5. https://doi.org/10.1038/nature17180.
- 589 [32] Agostini ML, Andres EL, Sims AC, Graham RL, Sheahan TP, Lu X, et al.
- 590 Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated
- 591 by the Viral Polymerase and the Proofreading Exoribonuclease. MBio 2018;9.
- 592 https://doi.org/10.1128/mBio.00221-18.
- 593 [33] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and
- chloroquine effectively inhibit the recently emerged novel coronavirus (2019-

- 595 nCoV) in vitro. Cell Res 2020;30:269–71. https://doi.org/10.1038/s41422-020596 0282-0.
- 597 [34] Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure
  598 against neglected and emerging RNA viruses. Antiviral Res 2018;153:85–94.
  599 https://doi.org/10.1016/j.antiviral.2018.03.003.
- 600 [35] Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS:
  601 A new trick for an old drug? CMAJ 2003;168:1289–92.
- 602 [36] Chan KW, Wong VT, Tang SCW. COVID-19: An Update on the
- 603 Epidemiological, Clinical, Preventive and Therapeutic Evidence and
- 604 Guidelines of Integrative Chinese–Western Medicine for the Management of
- 605 2019 Novel Coronavirus Disease. Am J Chin Med 2020:1–26.
- 606 https://doi.org/10.1142/s0192415x20500378.
- 607 [37] Wang R-R, Yang Q-H, Luo R-H, Peng Y-M, Dai S-X, Zhang X-J, et al.
- Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug
- 609 combination features and better inhibition on drug-resistant strains than
- 610 lamivudine in vitro. PLoS One 2014;9:e105617.
- 611 https://doi.org/10.1371/journal.pone.0105617.
- 612 [38] Rolain J-M, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl
- analogue to face bacterial, fungal and viral infections in the 21st century. Int J
  Antimicrob Agents 2007;30:297–308.
- 615 https://doi.org/10.1016/j.ijantimicag.2007.05.015.
- 616 [39] Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res
- 617 2020;177. https://doi.org/10.1016/j.antiviral.2020.104762.
- 618 [40] Colson P, Rolain J-M, Raoult D. Chloroquine for the 2019 novel coronavirus
- 619 SARS-CoV-2. Int J Antimicrob Agents 2020;55:105923.
- 620 https://doi.org/10.1016/j.ijantimicag.2020.105923.

621	[41]	Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Antiviral effects of
622		chloroquine Effects of chloroquine on viral infections : an old drug against
623		today 's diseases ? Lancet 2003;3:722-7. https://doi.org/10.1016/S1473-
624		3099(03)00806-5.
625	[42]	Savarino A, Di Trani L, Donatelli I, Cauda R, Cassone A. New insights into the
626		antiviral effects of chloroquine. Lancet Infect Dis 2006;6:67–9.
627		https://doi.org/10.1016/S1473-3099(06)70361-9.
628	[43]	Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al.
629		Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of
630		an open-label non-randomized clinical trial. Int J Antimicrob Agents
631		2020:105949. https://doi.org/10.1016/j.ijantimicag.2020.105949.
632	[44]	Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown
633		apparent efficacy in treatment of COVID-19 associated pneumonia in clinical
634		studies. Biosci Trends 2020;14:72-3. https://doi.org/10.5582/bst.2020.01047.
635	[45]	Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al.
636		COVID-19: consider cytokine storm syndromes and immunosuppression.
637		Lancet (London, England) 2020;395:1033-4. https://doi.org/10.1016/S0140-
638		6736(20)30628-0.
639	[46]	Chen C, Zhang XR, Ju ZY, He WF. [Advances in the research of cytokine
640		storm mechanism induced by Corona Virus Disease 2019 and the
641		corresponding immunotherapies]. Zhonghua Shao Shang Za Zhi 2020;36:E005.
642		https://doi.org/10.3760/cma.j.cn501120-20200224-00088.
643	[47]	Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical
644		features of 29 patients with 2019 novel coronavirus pneumonia]. Zhonghua Jie
645		He Hu Xi Za Zhi 2020;43:203–8. https://doi.org/10.3760/cma.j.issn.1001-
646		0939.2020.03.013.

- 647 [48] Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of
  648 Severe COVID-19 Patients with Tocilizumab. n.d.
- 649 [49] Demidowich AP, Davis AI, Dedhia N, Yanovski JA. Colchicine to decrease
- 650 NLRP3-activated inflammation and improve obesity-related metabolic
- dysregulation. Med Hypotheses 2016;92:67–73.
- 652 https://doi.org/10.1016/j.mehy.2016.04.039.
- [50] Min J-Y, Jang YJ. Macrolide therapy in respiratory viral infections. Mediators
  Inflamm 2012;2012:649570. https://doi.org/10.1155/2012/649570.
- 655 [51] Kanoh S, Rubin BK. Mechanisms of action and clinical application of
- 656 macrolides as immunomodulatory medications. Clin Microbiol Rev
- 657 2010;23:590–615. https://doi.org/10.1128/CMR.00078-09.
- 658 [52] Russell CD, Millar JE, Baillie JK. Clinical evidence does not support
- 659 corticosteroid treatment for 2019-nCoV lung injury. Lancet 2020;395:473–5.
- 660 https://doi.org/10.1016/S0140-6736(20)30317-2.
- 661 [53] Important Announcement of new SSC Guidelines COVID-19 ESICM n.d.
- https://www.esicm.org/ssc-covid19-guidelines/ (accessed April 2, 2020).
- 663 [54] Sallard E, Lescure F-X, Yazdanpanah Y, Mentre F, Peiffer-Smadja N, C-20-15
- 664 DisCoVeRy French Steering Committee. Type 1 interferons as a potential
- treatment against COVID-19. Antiviral Res 2020:104791.
- 666 https://doi.org/10.1016/j.antiviral.2020.104791.
- 667 [55] Angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor
- blockers in COVID-19 CEBM n.d. https://www.cebm.net/covid-
- 669 19/angiotensin-converting-enzyme-ace-inhibitors-and-angiotensin-receptor-
- 670 blockers-in-covid-19/ (accessed April 2, 2020).
- 671 [56] Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of
  672 2019-nCoV. Biochem Biophys Res Commun 2020.

- 673 https://doi.org/10.1016/j.bbrc.2020.02.071.
- 674 [57] Heurich A, Hofmann-Winkler H, Gierer S, Liepold T, Jahn O, Pohlmann S.
- 675 TMPRSS2 and ADAM17 Cleave ACE2 Differentially and Only Proteolysis by
- 676 TMPRSS2 Augments Entry Driven by the Severe Acute Respiratory Syndrome
- 677 Coronavirus Spike Protein. J Virol 2014;88:1293–307.
- 678 https://doi.org/10.1128/jvi.02202-13.
- 679 [58] Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the
- 680 COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-
- 681 Angiotensin System Blockers. Hypertens (Dallas, Tex 1979)
- **682** 2020:HYPERTENSIONAHA12015082.
- 683 https://doi.org/10.1161/HYPERTENSIONAHA.120.15082.
- 684 [59] Hanff TC, Harhay MO, Brown TS, Cohen JB, Mohareb AM. Is There an
- 685 Association Between COVID-19 Mortality and the Renin-Angiotensin System-
- a Call for Epidemiologic Investigations. Clin Infect Dis 2020.
- 687 https://doi.org/10.1093/cid/ciaa329.
- 688 [60] Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et
- al. Camostat Mesilate, Pancrelipase, and Rabeprazole Combination Therapy
- 690 Improves Epigastric Pain in Early Chronic Pancreatitis and Functional
- 691 Dyspepsia with Pancreatic Enzyme Abnormalities. Digestion 2019;99:283–92.
  692 https://doi.org/10.1159/000492813.
- 693 [61] Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S.
- 694 The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor
- ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv
- 696 2020:2020.01.31.929042. https://doi.org/10.1101/2020.01.31.929042.
- 697 [62] Blaising J, Polyak SJ, Pécheur E-I. Arbidol as a broad-spectrum antiviral: an
  698 update. Antiviral Res 2014;107:84–94.

- 699 https://doi.org/10.1016/j.antiviral.2014.04.006.
- 700 [63] Fink SL, Vojtech L, Wagoner J, Slivinski NSJ, Jackson KJ, Wang R, et al. The
- 701 Antiviral Drug Arbidol Inhibits Zika Virus. Sci Rep 2018;8:8989.
- 702 https://doi.org/10.1038/s41598-018-27224-4.
- 703 [64] Hulseberg CE, Fénéant L, Szymańska-de Wijs KM, Kessler NP, Nelson EA,
- 704 Shoemaker CJ, et al. Arbidol and Other Low-Molecular-Weight Drugs That
- 705 Inhibit Lassa and Ebola Viruses. J Virol 2019;93.
- 706 https://doi.org/10.1128/jvi.02185-18.
- 707 [65] Shi L, Xiong H, He J, Deng H, Li Q, Zhong Q, et al. Antiviral activity of
- arbidol against influenza A virus, respiratory syncytial virus, rhinovirus,
- 709 coxsackie virus and adenovirus in vitro and in vivo. Arch Virol

710 2007;152:1447–55. https://doi.org/10.1007/s00705-007-0974-5.

- 711 [66] Deng P, Zhong D, Yu K, Zhang Y, Wang T, Chen X. Pharmacokinetics,
- metabolism, and excretion of the antiviral drug arbidol in humans. Antimicrob
- 713 Agents Chemother 2013;57:1743–55. https://doi.org/10.1128/AAC.02282-12.
- 714 [67] Glushkov RG, Gus'kova TA, Krylova LI, Nikolaeva IS. [Mechanisms of
- 715 arbidole's immunomodulating action]. Vestn Ross Akad Meditsinskikh Nauk
  716 1999:36–40.
- 717 [68] Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with
- 718 LPV/r versus LPV/r alone against Corona Virus Disease 2019:a retrospective
- 719 cohort study. J Infect 2020. https://doi.org/10.1016/j.jinf.2020.03.002.
- 720 [69] Sahr F, Ansumana R, Massaquoi TA, Idriss BR, Sesay FR, Lamin JM, et al.
- 721 Evaluation of convalescent whole blood for treating Ebola Virus Disease in
- Freetown, Sierra Leone. J Infect 2017;74:302–9.
- 723 https://doi.org/10.1016/j.jinf.2016.11.009.
- 724 [70] Wong VWS, Dai D, Wu AKL, Sung JJY. Treatment of severe acute respiratory


725		syndrome with convalescent plasma. Hong Kong Med J 2003;9:199–201.
726	[71]	Cheng Y, Wong R, Soo YOY, Wong WS, Lee CK, Ng MHL, et al. Use of
727		convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin
728		Microbiol Infect Dis 2005;24:44-6. https://doi.org/10.1007/s10096-004-1271-
729		9.
730	[72]	Soo YOY, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KKS, et al.
731		Retrospective comparison of convalescent plasma with continuing high-dose
732		methylprednisolone treatment in SARS patients. Clin Microbiol Infect
733		2004;10:676-8. https://doi.org/10.1111/j.1469-0691.2004.00956.x.
734	[73]	Mair-Jenkins J, Saavedra-Campos M, Baillie JK, Cleary P, Khaw F-M, Lim
735		WS, et al. The effectiveness of convalescent plasma and hyperimmune
736		immunoglobulin for the treatment of severe acute respiratory infections of viral
737		etiology: a systematic review and exploratory meta-analysis. J Infect Dis
738		2015;211:80-90. https://doi.org/10.1093/infdis/jiu396.
739	[74]	Arabi YM, Hajeer AH, Luke T, Raviprakash K, Balkhy H, Johani S, et al.
740		Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV
741		Infection, Saudi Arabia. Emerg Infect Dis 2016;22:1554–61.
742		https://doi.org/10.3201/eid2209.151164.
743	[75]	Cao W-C, Liu W, Zhang P-H, Zhang F, Richardus JH. Disappearance of
744		antibodies to SARS-associated coronavirus after recovery. N Engl J Med
745		2007;357:1162-3. https://doi.org/10.1056/NEJMc070348.
746	[76]	Loy H, Kuok DIT, Hui KPY, Choi MHL, Yuen W, Nicholls JM, et al.
747		Therapeutic Implications of Human Umbilical Cord Mesenchymal Stromal
748		Cells in Attenuating Influenza A(H5N1) Virus-Associated Acute Lung Injury. J
749		Infect Dis 2019;219:186–96. https://doi.org/10.1093/infdis/jiy478.
750	[77]	Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of
		32

- ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with
- 752 COVID-19 Pneumonia. Aging Dis 2020;11:216.
- 753 https://doi.org/10.14336/ad.2020.0228.
- Yu B, Zhang X, Li X. Exosomes derived from mesenchymal stem cells. Int J
  Mol Sci 2014;15:4142–57. https://doi.org/10.3390/ijms15034142.
- 756 [79] Yin K, Wang S, Zhao RC. Exosomes from mesenchymal stem/stromal cells: A
- new therapeutic paradigm. Biomark Res 2019;7.
- 758 https://doi.org/10.1186/s40364-019-0159-x.
- 759 [80] Di Paolo N, Bocci V, Gaggiotti E. Ozone therapy. Int J Artif Organs
- 760 2004;27:168–75. https://doi.org/10.1177/039139880402700303.
- 761 [81] Infection prevention and control n.d.
- 762 https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-
- 763 guidance/infection-prevention-and-control (accessed April 2, 2020).
- 764 [82] COVID-19 n.d. https://www.ecdc.europa.eu/en/covid-19-pandemic (accessed
  765 April 2, 2020).
- 766 [83] Moderna's COVID-19 vaccine could reach healthcare workers this fall
- 767 FierceBiotech n.d. https://www.fiercebiotech.com/biotech/moderna-s-covid-19-
- vaccine-could-reach-healthcare-workers-fall (accessed April 2, 2020).
- 769 [84] Johnson & Johnson identifies lead COVID-19 vaccine candidate n.d.
- 770 https://www.drugtargetreview.com/news/58911/johnson-johnson-identifies-
- 771 lead-covid-19-vaccine-candidate/ (accessed April 2, 2020).
- 772 [85] WHO R&D Blueprint novel Coronavirus COVID-19 Therapeutic Trial773 Synopsis. 2020.
- 774 [86] Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the
- adult respiratory distress syndrome. Am Rev Respir Dis 1988;138:720–3.
- 776 https://doi.org/10.1164/ajrccm/138.3.720.

- 777 [87] Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A
- 778 prediction rule to identify low-risk patients with community-acquired
- 779 pneumonia. N Engl J Med 1997;336:243–50.
- 780 https://doi.org/10.1056/NEJM199701233360402.
- 781 [88] Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, et al. COVID-19 infection:
  782 the perspectives on immune responses. Cell Death Differ 2020:1–4.
- 783 https://doi.org/10.1038/s41418-020-0530-3.
- 784 [89] Wu J, Li W, Shi X, Chen Z, Jiang B, Liu J, et al. Early antiviral treatment
- 785 contributes to alleviate the severity and improve the prognosis of patients with
- novel coronavirus disease (COVID-19). J Intern Med 2020.
- 787 https://doi.org/10.1111/joim.13063.
- 788 [90] To KK-W, Tsang OT-Y, Leung W-S, Tam AR, Wu T-C, Lung DC, et al.
- 789 Temporal profiles of viral load in posterior oropharyngeal saliva samples and
- serum antibody responses during infection by SARS-CoV-2: an observational
- cohort study. Lancet Infect Dis 2020;3099:1–10.
- 792 https://doi.org/10.1016/S1473-3099(20)30196-1.
- 793 [91] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of
- patients infected with 2019 novel coronavirus in Wuhan, China. Lancet
- 795 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.
- 796 [92] Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-
- 797 19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis
  798 2020;20:400–2. https://doi.org/10.1016/S1473-3099(20)30132-8.
- 799 [93] Diagnosis and Treatment Protocol for COVID-19 (Trial Version 7) n.d.
- 800 http://en.nhc.gov.cn/2020-03/29/c\_78469.htm (accessed April 2, 2020).
- 801 [94] Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al.
- First case of 2019 novel coronavirus in the United States. N Engl J Med

803		2020;382:929-36. https://doi.org/10.1056/NEJMoa2001191.
804	[95]	NIH clinical trial of investigational vaccine for COVID-19 begins   National
805		Institutes of Health (NIH) n.d. https://www.nih.gov/news-events/news-
806		releases/nih-clinical-trial-investigational-vaccine-covid-19-begins (accessed
807		April 2, 2020).
808	[96]	Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease
809		(COVID-19) in the Healthcare Setting - Full Text View - ClinicalTrials.gov
810		n.d. https://clinicaltrials.gov/ct2/show/NCT04303507 (accessed April 2, 2020).
811	[97]	Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and
812		diagnosis of COVID-19. J Pharm Anal 2020.
813		https://doi.org/10.1016/j.jpha.2020.03.001.
814	[98]	Cepheid   Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use
815		Authorization n.d. https://www.cepheid.com/coronavirus (accessed April 2,
816		2020).
817	[99]	Detect COVID-19 in as Little as 5 Minutes   Abbott Newsroom n.d.
818		https://www.abbott.com/corpnewsroom/product-and-innovation/detect-covid-
819		19-in-as-little-as-5-minutes.html (accessed April 4, 2020).
820	[100]	Report of the WHO-China Joint Mission on Coronavirus Disease 2019
821		(COVID-19) n.d. https://www.who.int/publications-detail/report-of-the-who-
822		china-joint-mission-on-coronavirus-disease-2019-(covid-19) (accessed April 2,
823		2020).
824		
825		

#### 826 Figures:




827 Figure 1. Systematic review Flow Chart.

Figure 2. Currently tested therapeutic molecules targeting different steps of SARS-

#### CoV-2 life cycle.

#### 




#### 

## 


858 Figure 3.General and supportive therapeutic interventions tested for novel coronavirus


#### 859 disease (COVID-19).

860



874 Figure 4. Number of trials reported by the median of the total number of planned






876

877 Figure 5. Number of trials per total number of planned inclusions for the ten most

878 frequently assessed treatments.



879

880 Note: The size of the circle corresponds to the addition of the total numbers of

881 planned inclusions for all trials evaluating one of the treatments

### 883 Tables:

Table 1. Treatment interventions currently being evaluated for the novel coronavirus

Therapeutic	Countries	No. of trials	No. of RCTs	Other agents used in combination
Intervention		being tested	(% of trials per	
			intervention)	
TCMs	China	92	61 (66.3)	IFNα, LPV/r, Ribavirin, Chloroquine
				Umifenovir, Ulinastatin
Antimalaria drugs	China, France,	34	27 (79.4)	Azithromycin, LPV/r, DRV/r or c,
(hydroxychloroquine,	Germany, Mexico,			Favipiravir, Oseltamivir, Umifenovir,
chloroquine,	Norway, Spain, Brazil,			IFNα
dihydroartemisinin	Canada			
piperaquine)				
Lopinavir $\pm$ ritonavir	China, Thailand, Hong	32	31 (96.8)	Chloroquine, IFNα, IFNβ, Navaferon
$(LPV \pm r)$	Kong, United			Thymosin a1, FTC/TAF, Ribavirin,
	Kingdom, Europe,			Ebastine, Oseltamivir, Favipiravir,
	South Korea, Canada			TCM
Cell therapy	China, USA, Brazil,	30	18 (60)	Ruxolitinib
	Jordan			
Interferon (IFNα,	China, UK, Hong	22	22 (100)	Umifenovir, Dihydroartemisinine
ΙΓΝα2β, ΙΓΝβ,	Kong, Europe			piperaquine, TCM, Bromhexine,
rSIFN-co)				Favipiravir, LPV/r, Ribavirin,
				Ebastine, Danoprevir/r, Thalidomide,
				Methylprednisolone, TTF2
Anti-IL-6 mAb	China, Italy, France,	14	9 (64.3)	Favipiravir, Adalimumab
(Tocilizumab,	Switzerland, Denmark,			
Sarilumab)	USA, Canada, Global			
Dietary/Supportive	China, Egypt	13	10 (76.9)	N/A
Corticosteroids	China, UK, Italy	11	9 (81.8)	IFNα Umifenovir, Thalidomide
Umifenovir	China	11	11 (100)	Novaferon, IFNα, IFNα2β,
				Dihydroartemisinine piperaquine,
				Bromhexine, Favipiravir,

disease (COVID-19) globally.

Thalidomide, Methylprednisolone

Convalescent plasma	China, Italy	10	7 (70)	N/A
Adjuvant Device	China	9	3 (33.3)	N/A
Favipiravir	China, Thailand	8	8 (100)	Tocilizumab, Bromhexine, IFNα,
				Umifenovir, (Hydroxy)chloroquine,
				LPV/r, DRV/r
Remdesivir	Global, Europe, USA,	8	7 (87.5)	Hydroxychloroquine
	China			
Ventilation/ Oxygenation	China	7	0 (0)	N/A
strategies				
Macrolides	China, Brazil,	4	4 (100)	Hydroxychloroquine
(azithromycin,	Denmark			
carrimycin)				
Inhaled Gases	China, USA, Italy	4	4 (100)	N/A
JAK inhibitors	China, Italy, Canada	4	2 (50)	Cell therapy, Ritonavir
(Jakotinib, Ruxolitinib,				
Baricitinib)				
ACE inhibitor / ARBs	China, USA	3	2 (66.7)	N/A
Azvudine	China	3	1 (33.3)	N/A
Danoprevir/ritonavir	China	3	3 (100)	IFN
Darunavir/cobicistat	China, Thailand	3	3 (100)	Thymosin a1, Oseltamivir,
(DRV/r)				Hydroxychloroquine, Favipiravir
Pirferidone	China	3	3 (100)	N/A
Anti-PD-1 mAb	China	3	3 (100)	N/A
Oseltamivir	Thailand, China	3	3 (100)	Hydroxychloroquine, DRV/r, LPV/r
Thymosin a1	China	3	3 (100)	DRV/c, LPV/r
Adalimumab	China	2	2 (100)	Tocilizumab
Bevazicumab	China, Italy	2	1 (50)	N/A
Colchicine	Italy, Canada	2	2 (100)	N/A
Novaferon	China	2	2 (100)	LPV/r, Umifenovir
Ribavirin	China, Hong Kong	2	2 (100)	IFN, LPV/r
Thalidomide	China	2	2 (100)	IFNα, Umifenovir,
				Methylprednisolone
Ulinastatin	China	2	1 (50)	TCM

ASC09/ritonavir	China	2	2 (100)	N/A
Intravenous	China	2	2 (100)	N/A
Immunoglobulin				
Acetylcysteine	China	1	1 (100)	N/A
Antiviral peptide LL-37	China	1	0 (0)	N/A
Baloxavir Marboxil	China	1	1 (100)	N/A
Bismuth potassium	China	1	1 (100)	N/A
Bronchoscopic alveolar	China	1	0 (0)	N/A
lavage				
CD24Fc	USA	1	1 (100)	N/A
Dipyridamole	China	1	1 (100)	N/A
Ebastine	China	1	1 (100)	IFNa, LPV/r
Eculizumab	N/A	1	0 (0)	N/A
Enoxaparin	China	1	1 (100)	N/A
Escin	Italy	1	0 (0)	N/A
Fingolimod	China	1	0 (0)	N/A
FTC/TAF	China	1	1 (100)	LPV/r
hrIL-2	China	1	1 (100)	N/A
Inactivated	China	1	1 (100)	N/A
mycobacterial vaccine				
Itraconazole	Belgium	1	1 (100)	N/A
Ixekizuman	China	1	1 (100)	IFNα, Ribavirin, Chloroquine, LPV/r,
				Umifenovir
Leflunomide	China	1	1 (100)	N/A
M1	China	1	1 (100)	N/A
Polyinosinic/	China	1	1 (100)	N/A
polycytidylic acid				
rhG-CSF	China	1	1 (100)	N/A
Sargramostin (GM-CSF)	Belgium	1	1 (100)	N/A
Sildenafil	China	1	0 (0)	N/A
Siltuximab	Italy	1	0 (0)	N/A
Suramin	China	1	0 (0)	N/A
T89	N/A	1	1 (100)	N/A

TFF-2	China	1	1 (100)	IFN-κ
TMPRSS2 inhibitor	Denmark	1	1 (100)	N/A
(camostat mesylate)				
Tranilast	China	1	1 (100)	N/A
VIP	USA, Israel	1	1 (100)	N/A
vMIP	China	1	0 (0)	N/A
Meplazumab (anti-	China	1	1 (100)	N/A
CD147)				
Sodium Aescinate	China	1	1 (100)	N/A
Triazavirin	China	1	1 (100)	N/A

ACE: Angiotensin converting enzyme, Anti-PD-1 mAb: Anti Program Cell Death Protein-1 monoclonal antibody, ARBs: Angiotensin II receptor blockers, CD24Fc: CD24 extracellular domain-IgG1 Fc domain recombinant fusion protein, DRV/r or c: Darunavir/ritonavir or cobicistat, FTC/TAF: Emtricitabine/Tenofovir alafenamide, GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor, hrIL-2: human recombinant interleukin 2, IFNα: Interferon alpha, IFNβ: Interferon beta, INFκ: Interferon kappa, IL: Interleukin, JAK: Janus Kinases, LPV/r: Lopinavir/ritonavir, M1: Type I Macrophage, N/A: Not applicable, RCTs: Randomised controlled trials, rhG-CSF: recombinant human Granulocyte-Colony Stimulating Factor, TCMs: Traditional Chinese Medicines, TMPRSS2: Transmembrane Protease Serine 2, TTF-2: Transcription Termination Factor 2, UK: United Kingdom, USA: United States of America, VIP: Vasoactive Intestinal Peptide, vMIP: viral Macrophage Inflammatory Protein.

886

888 Table 2. Prevention interventions currently being evaluated for the novel coronavirus

Prevention	Countries	No. of trials	No. of RCTs	Other agents used in combination
intervention		being tested	(% of trials per	
			intervention)	
TCMs	China	10	3 (30)	N/A
Antimalaria Drugs	China, USA, Mexico,	6	6 (100)	Umifenovir, DRV/c
	UK, Spain			
Vaccine	USA, China	4	0 (0)	N/A
Health education	China, Hungary	3	2 (66.7)	TCM
IFNα1β	China	2	0 (0)	Thymosin a1
Darunavir/cobicistat	Spain	1	1 (100)	Chloroquine
Lopinavir/ritonavir	Canada	1	1 (100)	N/A
Mask	Canada	1	1 (100)	N/A
PUL-042	USA	1	1 (100)	N/A
Thymosin a1	China	1	0 (0)	ΙFNα1β
Umifenovir	China	1	1 (100)	Hydroxychloroquine

disease (COVID-19) globally.

DRV/c: Darunavir/cobicistat, IFNa: Interferon alpha, LPV/r: Lopinavir/ritonavir, N/A: Not applicable, RCTs: Randomised

controlled trials, TCMs: Traditional Chinese Medicines, UK: United Kingdom, USA: United States of America.

890

Study characteristics		Treatment studies	Prevention studies
		N = 198 (%)	N = 16 (%)
Study phase			
	Phase I	9 (5)	3 (19)
	Phase II*	31 (16)	2 (13)
	Phase III**	35 (18)	6 (38)
	Phase IV	40 (20)	1 (6)
	Unspecified	83 (42)	4 (25)
Study design			
	Randomised	150 (76)	10 (63)
	Non-randomised	21 (11)	3 (19)
	Single-arm	27 (14)	3 (19)
Blinding			
	Double-blind	31 (16)	6 (38)
	Single-blind	16 (8)	2 (13)
	Open-label	73 (37)	5 (31)
	Non-applicable <sup>†</sup>	29 (15)	3 (19)
	Unspecified	49 (25)	0 (0)
Total number of planned	linclusions		
	<50	62 (31)	1 (6)
	50-100	41 (21)	0 (0)
	100-150	32 (16)	3 (19)
	150-200	9 (5)	0 (0)
	200-250	15 (8)	1 (6)
	≥250	39 (20)	11 (69)
Primary endpoint			
	Clinical	128 (65)	13 (81)
	Virological	39 (20)	2 (13)
	Radiological	19 (10)	0 (0)
	Immunological/biological	12 (6)	1 (6)

## 892 Table 3. Description of the clinical trials registered for the treatment and prevention of

## 893 COVID-19.

\*Including phase I/II trials; \*\*Including phase II/III trials; †: Single-arm or factorial trials.